Single-dose telitacicept therapy for refractory idiopathic membranous nephropathy: A case series

IF 0.6 Q3 MEDICINE, GENERAL & INTERNAL Clinical Case Reports Pub Date : 2024-11-06 DOI:10.1002/ccr3.9553

Liping Sun, Fuce Chen, Xinzhou Zhang

{"title":"Single-dose telitacicept therapy for refractory idiopathic membranous nephropathy: A case series","authors":"Liping Sun, Fuce Chen, Xinzhou Zhang","doi":"10.1002/ccr3.9553","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Key Clinical Message</h3>\n \n <p>We report three cases of IMN from our center, where patients received a single dose of telitacicept after showing no response to conventional treatments. Although one case did not respond, the other two cases achieved complete or partial remission of proteinuria. These cases illustrates the telitacicept may offer new hope for the treatment of IMN.</p>\n </section>\n \n <section>\n \n \n <p>Despite the variety of treatment options available, effective therapies for refractory membranous nephropathy remain lacking. Recently, some reports have suggested that telitacicept is a new therapeutic option. However, only a few published studies have documented the use of telitacicept for treating idiopathic membranous nephropathy (IMN). We present three cases of IMN from our center, where patients received a single dose of telitacicept after showing no response to conventional treatments, including glucocorticoids, tacrolimus, mycophenolate mofetil, cyclophosphamide, cyclosporine, and rituximab. Although one case did not respond, the other two cases achieved complete or partial remission of proteinuria. Thus, telitacicept may offer new hope for the treatment of refractory membranous nephropathy.</p>\n </section>\n </div>","PeriodicalId":10327,"journal":{"name":"Clinical Case Reports","volume":"12 11","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540803/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ccr3.9553","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Key Clinical Message

We report three cases of IMN from our center, where patients received a single dose of telitacicept after showing no response to conventional treatments. Although one case did not respond, the other two cases achieved complete or partial remission of proteinuria. These cases illustrates the telitacicept may offer new hope for the treatment of IMN.

Despite the variety of treatment options available, effective therapies for refractory membranous nephropathy remain lacking. Recently, some reports have suggested that telitacicept is a new therapeutic option. However, only a few published studies have documented the use of telitacicept for treating idiopathic membranous nephropathy (IMN). We present three cases of IMN from our center, where patients received a single dose of telitacicept after showing no response to conventional treatments, including glucocorticoids, tacrolimus, mycophenolate mofetil, cyclophosphamide, cyclosporine, and rituximab. Although one case did not respond, the other two cases achieved complete or partial remission of proteinuria. Thus, telitacicept may offer new hope for the treatment of refractory membranous nephropathy.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

单剂量泰利他赛治疗难治性特发性膜性肾病：病例系列。

关键临床信息：我们报告了本中心的三例IMN病例，患者在接受常规治疗无效后接受了单剂量替利他赛。虽然其中一例患者没有反应，但另外两例患者的蛋白尿得到了完全或部分缓解。这些病例说明，替立替塞普可能会为治疗膜性肾病带来新的希望。摘要：尽管治疗方法多种多样，但仍缺乏治疗难治性膜性肾病的有效疗法。最近，一些报道认为替立替塞是一种新的治疗选择。然而，只有少数已发表的研究记录了替利他赛普用于治疗特发性膜性肾病（IMN）。我们介绍了本中心的三例特发性膜性肾病病例，患者在对糖皮质激素、他克莫司、霉酚酸酯、环磷酰胺、环孢素和利妥昔单抗等常规治疗无效后接受了单剂量替利他赛普治疗。虽然其中一个病例没有反应，但另外两个病例的蛋白尿得到了完全或部分缓解。因此，替立替塞普为治疗难治性膜性肾病带来了新希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Case Reports MEDICINE, GENERAL & INTERNAL-

自引率

14.30%

发文量

1268

审稿时长

13 weeks

期刊介绍： Clinical Case Reports is different from other case report journals. Our aim is to directly improve global health and increase clinical understanding using case reports to convey important best practice information. We welcome case reports from all areas of Medicine, Nursing, Dentistry, and Veterinary Science and may include: -Any clinical case or procedure which illustrates an important best practice teaching message -Any clinical case or procedure which illustrates the appropriate use of an important clinical guideline or systematic review. As well as: -The management of novel or very uncommon diseases -A common disease presenting in an uncommon way -An uncommon disease masquerading as something more common -Cases which expand understanding of disease pathogenesis -Cases where the teaching point is based on an error -Cases which allow us to re-think established medical lore -Unreported adverse effects of interventions (drug, procedural, or other).